Drugs / BCMA/GPRC5D dual CAR-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT06068400 | Sep 2023 → Feb 2024 | refractory plasma cell neoplasm | Guangzhou Bio-gene Technology Co., Ltd | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA/GPRC5D dual CAR-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06068400 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR) -T cell therapy targeting B-cell maturation antigen (BCMA) has demonstrated significant efficacy” PMID 40547010 ↗ Jun 2025 |
| Target | GPRC5D | “targeting G protein-coupled receptor C5 family member D (GPRC5D) provides a new therapeutic direction.” PMID 40547010 ↗ Jun 2025 |